This oral drug might make blood cancer treatment safer

A London-based startup, Poolbeg Pharma, is set to trial POLB 001 at six NHS hospitals, aiming to prevent cytokine release syndrome (CRS) in cancer immunotherapy patients.

Raccontata danewsbytesapp.com